Condition Focus: PBM Dosing — Why the Right Dose Matters More Than More Dose
If the de Freitas & Hamblin 2016 paper explains what PBM does, this paper from Huang, Chen, Carroll, and Hamblin explains why doing it right matters. Published in Dose-Response and cited over 1000 times, it defines the Arndt-Schulz curve for photobiomodulation — the biphasic dose-response relationship that governs every PBM outcome.
The principle is straightforward: at low energy densities, PBM produces no measurable biological effect (insufficient stimulus). As dose increases into the therapeutic window (~1–4 J/cm²), cellular responses increase proportionally — ATP production rises, inflammation decreases, repair programmes activate. Beyond the optimum, further dose increases produce diminishing returns and eventually inhibitory or negative effects. The curve looks like an inverted U.
This is not unique to PBM — exercise, pharmaceuticals, radiation, and most biological stimuli follow the same pattern. But for PBM, the Arndt-Schulz curve has specific practical consequences: it means that a device delivering 4 J/cm² will produce better outcomes than one delivering 40 J/cm², and that a device with precisely controlled, repeatable dosing will outperform one with variable or poorly characterised output.
The paper reviews biphasic responses across multiple biological endpoints: ATP production, mitochondrial membrane potential, ROS generation, NF-κB activation, cell proliferation, wound healing, and pain modulation. In every case, the inverted-U pattern holds. The optimum window consistently falls in the 1–4 J/cm² range for most tissue types.
For gout, the dosing principle has immediate practical relevance: more treatment sessions at the correct dose will produce better outcomes than fewer sessions at excessive dose. The G.O.A.T.’s automated dosing protocol is designed to hit the therapeutic window every time, removing the guesswork that could push patients into the inhibitory range.
G.O.A.T. for Gout Alignment: The G.O.A.T.’s 4 J/cm² target fluence sits at the upper end of the 1–4 J/cm² optimum window identified in this paper. The ~13-minute session duration and 5 mW/cm² irradiance are calculated to deliver this precise dose. This paper is the scientific rationale for the G.O.A.T.’s parameter selection.
Link to original research here
Editor’s note: The biphasic NF-κB response predicted here is directly demonstrated in Chen et al 2011. The hormetic mitochondrial response at specific wavelengths is shown in PBM and Oxidative Stress 2022. The cell-type specific dose optima for bone cells are mapped in Na et al 2018. The macrophage dose-dependent polarization at 5 J/cm² optimum is confirmed in Tian et al 2023.
Related Articles
- PBM Activates NF-κB via Mitochondrial ROS at 810nm – Chen et al 2011
- PBM and Oxidative Stress: Mitochondrial Activity Regulation – 2022
- Dose Analysis of PBM on Osteoblast, Osteoclast, and Osteocyte – Na et al 2018
- PBM Increases M2 Macrophages via PI3K/AKT/mTOR at 980nm – Tian et al 2023
- Proposed Mechanisms of PBM – de Freitas & Hamblin 2016
Key Takeaways
- Arndt-Schulz curve: low dose = no effect; optimal dose = maximum benefit; excessive dose = inhibition
- Optimum window consistently 1–4 J/cm² across multiple biological endpoints
- More light is not better — precision dosing outperforms maximum output
- Cited 1000+ times — THE reference for PBM dosing rationale
Study Overview
| Study Type: | Mechanistic review (foundational) |
| Wavelength(s): | Red (600–700 nm) + NIR (780–940 nm); 810 nm primary |
| Treatment Protocol: | 0.001–50+ J/cm²; optimum ~1–4 J/cm² |
| Sample Size: | Review of biphasic response studies across endpoints |
| Primary Outcome: | Arndt-Schulz biphasic curve confirmed across ATP, ROS, NF-κB, proliferation, healing |
Full Citation
Huang YY, Chen AC, Carroll JD, Hamblin MR. (2009). Biphasic dose response in low level light therapy. Dose-Response, 7(4), 358–383. View Publication
